Department of OBGYN

Anda Vlad, MD, PhD

  • Associate Professor, Department of Obstetrics, Gynecology & Reproductive Sciences

Education & Training

  • Postdoctoral Fellow, University of Pittsburgh School of Medicine, Pittsburgh PA
  • PhD, Immunology, University of Pittsburgh School of Medicine, Pittsburgh PA
  • MD, University of Medicine and Pharmacy, Craiova, Romania

Representative Publications

  • Grabosch S*, Bulatovic M*, Zeng F, Ma T, Zhang L, Ross M, Brozick J, Fang Y, Tseng G, Kim E Gambotto A, Elishaev E, Edwards RP and Vlad AM. Cisplatin-induced immune modulation in ovarian cancer mouse models with distinct inflammation profiles. Oncogene. 2019 Mar;38(13):2380-2393 PMID: 30518877
  • ​Grabosch S, Tseng G, Edwards RP, Lankes HA, Moore K, Odunsi K, Vlad AM, Ma T, Strange M, Brozick J, Lugade A, Omilian A, Bshara W, Stuckey AR, Walker JL, Brady MF and Birrer M. Multiplex profiling identifies distinct local and systemic alterations during intraperitoneal chemotherapy for ovarian Cancer:  an NRG Oncology/Gynecologic Oncology Group Study. Gynecologic Oncology. 2017 Jul;146(1):137-145. PMID: 28483269.
  • Zhang L, Ma T, Brozick J, Babalola K, Budiu R, Tseng G and Vlad AM. Effects of Kras activation and Pten deletion alone or in combination on MUC1 biology and epithelial-to-mesenchymal transition in ovarian cancer. Oncogene. 2016 Mar 14. PMID: 26973247.
  • ​Mony, JT, Zhang L, Ma T, Grabosch S Tirodkar T, Brozick J, Tseng G, Elishaev E, Edwards RP, Huang H and Vlad AM. Anti-PD-L1 prolongs survival and triggers T cell but not humoral anti-tumor immune responses in a human MUC1- expressing preclinical ovarian cancer model. Cancer Immunology Immunotherapy 2015 May 22. PMID: 25998800.
  • Suryawanshi S, Huang X, Elishaev E, Budiu RA, Zhang L, Kim S, Donnellan N, Mantia-Smaldone G, Ma T, Tseng G, Lee T, Mansuria S, Edwards RE and Vlad AM. Complement Pathway is Frequently Altered in Endometriosis and Endometriosis-Associated Ovarian Cancer. Clinical Cancer Research Oct 2014, PMID: 25294912
  • Suryawanshi S*, Vlad AM*, Lin HM, Mantia-Smaldone G, Laskey R, Lee M, Lin Y, Donnellan N, Klein-Patel M, Lee T, Mansuria S, Elishaev E, Budiu R, Edwards RP, Huang X. (*Authors with equal contributions). Plasma microRNAs as novel biomarkers for endometriosis and endometriosis-associated ovarian cancer. Clinical Cancer Research 2013 Mar; 19(5):1213-24. PMID: 23362326.

For additional publications, see: (Pubmed or other online collection) http://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/43141884/

Clinical Interests/Research Interests

The Vlad Lab focuses on:

  1. Development of new preclinical models for ovarian cancer and early precursors;
  2. Development of new immune modulators for ovarian cancer immunotherapy;
  3. Implementation of new combination treatment regimens in early phase clinical trials and identification of immune biomarkers of response.

Research Grants

Our lab funding is provided by the NIH, Department of Defense, Pennsylvania Department of Health and private foundations.